A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years

NCT03962062 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Onchocerciasis

Interventions

DRUG: Moxidectin

Sponsor

Medicines Development for Global Health